Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSichuan University
About this trial
The Purpose of This Study is to Evaluate the Efficacy and Safety of Gemox combined with Anlotinib and Sintilimab as first-lineTherapy for Patients With advanced combined hepatocellular-cholangiocarcinoma.
Eligibility criteria
Qualifiers
.Age 18-75 years;
.Histologically or cytologically confirmed diagnosis of aCombined hepatocellular-cholangiocarcinoma;
.Non resectable or metastatic cHCC-ICC patients who have not received systemic treatment or first-line treatment progress (only non arotinib Targeted therapy or non GEMOX chemotherapy) in the past, and have at least one measurable lesion (RECIST v1.1);
.Life expectancy ≥ 3 months;
Disqualifiers
Has a history of severe allergic reactions to chimeric, human or humanized antibodies, or fusion proteins.
Pregnant or lactating women, men and women of childbearing age who are unwilling or unable to take effective contraceptive measures;
History of other malignant tumors in the past 5 years, except for malignant tumors that have received treatment for the purpose of cure, and have no known active diseases for ≥ 5 years before the first administration, and have a low potential risk of recurrence; Fully treated non Melanoma skin cancer or malignant lentigo without disease evidence; Fully treated Carcinoma in situ, no disease evidence;
Moderate or higher amounts of pleural and ascitic fluid with clinical symptoms;
Trial design
Treatments tested in this trial
- gemcitabine ,oxaliplatin,anlotinib,Sintilimab
Treatment groups
25 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov